- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Key Metrics
- Market Cap (In Cr) 13336
- Beta 0.54
- Div. Yield (%) 3.13
- P/B 5.99
- TTM P/E 14.7
- Peg Ratio -0.37
- Sector P/E 24.66
- D/E 0.02
- Open Price 5751.05
- Prev Close 5794.7
Analysis
-
1 Week-2.68%
-
3 Months-7.34%
-
6 Month-17.21%
-
YTD-21.28%
-
1 Year-20.25%
- 18% Low risk
- 18% Moderate risk
- 18% Balanced Risk
- 18% High risk
- 18% Extreme risk
8 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
- Ratings
- Current
- Strong Sell
- 1
- Sell
- 0
- Hold
- 1
- Buy
- 2
- Strong Buy
- 4
Sanofi India News
Three straight months of growth boosts pharma makers’ confidence
2 min read . 16 Sep 2022
Pharma stock announces 1930% special dividend. 5 things you should know
1 min read . 27 Jul 2022
This pharma firm declares a one-time special dividend of ₹193 per equity share
1 min read . 26 Jul 2022
These 2 companies to soon pay special dividends. Details here
1 min read . 21 Mar 2022Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2021
- Total Revenue
- 2956.6
- Selling/ General/ Admin Expenses Total
- 876.7
- Depreciation/ Amortization
- 66.7
- Other Operating Expenses Total
- -0.1
- Total Operating Expense
- 1771.5
- Operating Income
- 1185.1
- Net Income Before Taxes
- 1257.6
- Net Income
- 944.4
- Diluted Normalized EPS
- 248.4
- Period
- 2020
- Total Revenue
- 2901.9
- Selling/ General/ Admin Expenses Total
- 918
- Depreciation/ Amortization
- 82.2
- Other Operating Expenses Total
- -0.1
- Total Operating Expense
- 2309.8
- Operating Income
- 592.1
- Net Income Before Taxes
- 677.2
- Net Income
- 477.6
- Diluted Normalized EPS
- 221
- Period
- 2019
- Total Revenue
- 3070.6
- Selling/ General/ Admin Expenses Total
- 1034.3
- Depreciation/ Amortization
- 99.9
- Other Operating Expenses Total
- -0.3
- Total Operating Expense
- 2562.3
- Operating Income
- 508.3
- Net Income Before Taxes
- 599.9
- Net Income
- 414.2
- Diluted Normalized EPS
- 198.2
- Period
- 2018
- Total Revenue
- 2770.8
- Selling/ General/ Admin Expenses Total
- 954.9
- Depreciation/ Amortization
- 102.7
- Other Operating Expenses Total
- 22.8
- Total Operating Expense
- 2248.1
- Operating Income
- 522.7
- Net Income Before Taxes
- 609.8
- Net Income
- 380.6
- Diluted Normalized EPS
- 165.75
- Period
- 2017
- Total Revenue
- 2491.4
- Selling/ General/ Admin Expenses Total
- 895.9
- Depreciation/ Amortization
- 102.2
- Other Operating Expenses Total
- 31.9
- Total Operating Expense
- 2055
- Operating Income
- 436.4
- Net Income Before Taxes
- 514.6
- Net Income
- 326
- Diluted Normalized EPS
- 141.91
- Period
- 2016
- Total Revenue
- 2419.7
- Selling/ General/ Admin Expenses Total
- 769
- Depreciation/ Amortization
- 118.8
- Other Operating Expenses Total
- 32.3
- Total Operating Expense
- 2003.2
- Operating Income
- 416.5
- Net Income Before Taxes
- 480.4
- Net Income
- 304.2
- Diluted Normalized EPS
- 132.03
Forecast
Technical
- 5 Day5859.82
- 10 Day5930.96
- 20 Day6018.01
- 50 Day6217.58
- 100 Day6301.99
- 300 Day6632.49
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Ajanta Pharma
- 1265
- -11.25
- -0.88
- 1577.53
- 1062.2
- 16309.69
- J B Chemicals & Pharmaceuticals
- 1915
- 0.8
- 0.04
- 2045.8
- 1339.05
- 14805.1
- Sanofi India
- 5822.05
- 27.35
- 0.47
- 7860.67
- 5751.05
- 13336
- Alembic Pharmaceuticals
- 602.1
- 3.05
- 0.51
- 863.1
- 587.25
- 11789.86
- Suven Pharmaceuticals
- 454.45
- -4.35
- -0.95
- 623.51
- 410.25
- 11722.72
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 26-Jul-22
- Quarterly Results & Interim Dividend
- 26-Apr-22
- Quarterly Results
- 23-Feb-22
- Audited Results & Final Dividend
- 26-Oct-21
- Quarterly Results
- 27-Jul-21
- Quarterly Results
- 27-Apr-21
- Quarterly Results
- 23-Feb-21
- Audited Results & Final Dividend
Company Profile
ABOUT Sanofi India
- Industry Biotechnology & Drugs
- ISIN INE058A01010
- BSE Code 500674
- NSE Code SANOFI
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals products. The Company’s products are offered across four categories, which includes pharmaceuticals, consumer health care, vaccines and specialty care. It offers medicines for therapy areas, such as diabetes (both insulins and orals), cardiology, thrombosis, anti-infectives, central nervous system, allergy and vitamins, and minerals and supplements. Its pharmaceutical products include Adenocor, Lantus, Aldurazyme, AllStar, Amaryl MP, Amaryl M, Apidra, Arava, Aubagio and Thymoglobuline. Its specialty care products include Myozyme, Cerezyme, Aldurazyme, Aubagio and Jevtana. Its consumer healthcare products include Allegra, Allegra nasal, Avil, Combiflam, Combiflam Plus and Lactacyd. Its vaccines products include Adacel, Avaxim 80U/160U, FluQuadri, Hexaxim, Menactra, Tetraxim, Vaxigrip, Stamaril, Shanvac-B and ShanTT.
MANAGEMENT
- Vaibhav Karandikar Chief Financial Officer, Whole-Time Director
- Radhika Shah Compliance Officer, Company Secretary
- Rodolfo Hrosz Managing Director, Whole Time Director
- Cherian Mathew Whole Time Director
- Bratin Bag Senior Director - EBI, South Asia
- Gaurav Bahadur Senior Director - Human Resources, India and South Asia
- Shalini Menon Medical Head, India, India Medical Lead
- Vinita Patil Senior Legal Director - South Asia
- Yasmin Shenoy Senior Director - Regulatory Affairs
- Aparna Thomas Senior Director - Corporate Communications and Corporate Social Responsibility, India and South Asia
Company Summary
SANOFI INDIA SUMMARY
Sanofi India is trading 0.47% upper at Rs 5822.05 as compared to its last closing price. Sanofi India has been trading in the price range of 5822.2 & 5751.05. Sanofi India has given -21.28% in this year & -2.68% in the last 5 days.
Sanofi India has TTM P/E ratio 14.7 as compared to the sector P/E of 24.66. There are 8 analysts who have initiated coverage on Sanofi India. There are 4 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of 120.4 Crores in its last quarter.
Listed peers of Sanofi India include Ajanta Pharma (-0.88%), J B Chemicals & Pharmaceuticals (0.04%), Sanofi India (0.47%) etc.
FAQs about Sanofi India
- 1 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 1 analysts have given a hold rating
- 2 analysts have given a buy rating
- 4 analysts have given a strong buy rating
- TTM P/E: 14.7
- Sector P/E: 24.66
- Dividend Yield: 3.13%
- D/E ratio: -
